SIRPA and cancer: We further compared ZL-1201 with the benchmark in a variety of preclinical in vitro studies, and the data showed that ZL-1201 binds CD47 on multiple cancer cells, RBCs, and platelets (Fig. 1D; Supplementary Fig. S1C and S1D; Supplementary Fig. S1F and S1G), and blocks the interaction between CD47 and SIRPα (Fig. 1C; Supplementary Fig. S1B) with potency similar to that of the benchmark.